Efforts to develop an effective HIV vaccines have long faced setbacks, largely due to the virus’s extraordinary genetic diversity and the difficulty of directing the immune system to produce neutralizing antibodies that target the right viral structures. These antibodies, crucial for blocking infection, often fail to focus on the virus’s key “attach and enter” sites.
Current vaccine strategies rely heavily on soluble protein-based HIV-1 envelope glycoprotein (Env) trimers, which mimic the virus’s spike proteins. These are intended to train the immune system to recognize and neutralize conserved regions shared among many HIV strains. However, despite producing a strong antibody response, these trimers typically generate nonneutralizing antibodies that bind to less effective regions, such as the base of the Env trimer, without halting infection.
New Studies Highlight Promise of mRNA-Encoded Env Trimers
Two recent studies published in Science Translational Medicine mark a significant shift in strategy. Researchers at the Scripps Research Institute and Fred Hutchinson Cancer Center tested mRNA-based HIV vaccines that focus immune responses more precisely.
Reported by medicalxpress, the Scripps team developed an mRNA-encoded vaccine that instructs cells to produce either soluble or membrane-bound versions of a stabilized Env trimer known as BG505 MD39.3. The soluble version produces trimers that float freely outside cells, while the membrane-bound version anchors the trimers to the cell surface via a transmembrane domain.
Membrane-Bound Trimers Show Stronger Immune Response in Animal Models
In preclinical trials, the membrane-bound mRNA vaccine outperformed its soluble counterpart. Both rabbits and rhesus macaques produced neutralizing antibodies, particularly against the virus’s functional entry sites. Moreover, the membrane-bound vaccine triggered stronger CD8+ T cell responses and long-lasting plasma cells in bone marrow samples taken up to a year later.
Importantly, off-target B cell responses were less frequent in the membrane-bound group, indicating that the immune system was being steered more accurately toward the relevant viral targets.
Human Trial Demonstrates First Evidence of mRNA-Induced HIV Neutralization
Meanwhile, the Fred Hutchinson-led Phase 1 human trial offered the first clinical evidence that mRNA HIV vaccines can induce neutralizing antibodies. Involving 108 HIV-negative adults aged 18 to 55 across 10 U.S. sites, the study tested three vaccine constructs—two with membrane-bound trimers (one with a CD4-binding knockout mutation) and one with soluble trimers.
After three immunizations, 80% of participants receiving membrane-bound vaccines developed tier 2 neutralizing antibodies. These responses emerged after the second dose and strengthened with the third. Six months later, serum antibody levels remained detectable, and researchers found higher memory B cell responses targeting functional regions of the HIV Env trimer.
Mild Safety Signal Noted: Urticaria in a Small Percentage of Participants
Although the vaccine appeared largely safe, about 6.5% of participants developed mild-to-moderate chronic urticaria. While most symptoms resolved with antihistamines, a few individuals had lingering symptoms, and one case required short-term hospitalization. All vaccine versions were associated with this side effect, and researchers flagged it for further investigation.
A Measured Step Forward in HIV Vaccine Development
These findings underscore the potential of mRNA platforms to finally overcome longstanding roadblocks in HIV vaccine development. By anchoring Env trimers to cell membranes, scientists successfully directed the immune response toward neutralizing and protective sites on the virus.
While current antibodies remain largely strain-specific, this research sets the stage for future designs aimed at broadly neutralizing HIV variants. As researchers continue refining antigen structure and delivery strategies, mRNA vaccines may soon play a central role in the fight against HIV.